Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
May 15, 2024
May 13, 2024
May 13, 2024
May 8, 2024
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
May 6, 2024
April 18, 2024
April 11, 2024
March 28, 2024
March 25, 2024
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
March 21, 2024